Evidence map›Paper›PMID 33728396›Full record

ArticleRheumatology advances in practice2021

COVID-19 and shielding: experiences of UK patients with lupus and related diseases.

Melanie Sloan, Caroline Gordon, Elliott Lever, Rupert Harwood, Michael A Bosley, Mark Pilling, James Brimicombe, Felix Naughton, Moira Blane, Chanpreet Walia and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology advances in practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Melanie SloanDepartment of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge.
Caroline GordonRheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Science, University of Birmingham, Birmingham.
Elliott LeverRheumatology Department, Northwick Park Hospital, London.
Rupert HarwoodPatient and Public Involvement in Lupus Research Group, Institute of Public Health, University of Cambridge, Cambridge.ORCID https://orcid.org/0000-0001-9790-2796
Michael A BosleyPatient and Public Involvement in Lupus Research Group, Institute of Public Health, University of Cambridge, Cambridge.
Mark PillingDepartment of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge.
James BrimicombeDepartment of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Cambridge.
Felix NaughtonBehavioural and Implementation Science Group, School of Health Sciences, University of East Anglia, Norwich.
Moira BlanePatient and Public Involvement in Lupus Research Group, Institute of Public Health, University of Cambridge, Cambridge.
Chanpreet WaliaLUPUS UK, St James House, Romford.
David D'CruzThe Louise Coote Lupus unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
University of Cambridge · GBGuy's and St Thomas' NHS Foundation Trust · GBNorthwick Park Hospital · GBUniversity of Birmingham · GBUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe shielding guidance in the UK for the clinically extremely vulnerable (CEV) commenced on 23 March 2020 in response to the coronavirus disease 2019 (COVID-19) pandemic. The purpose of this study was to explore the impact of the pandemic and shielding on patients with lupus and related systemic autoimmune rheumatic diseases (SARDs).

methodsThis was a mixed-methods cohort study (

resultsMost participants had a high level of anxiety regarding their mortality risk from COVID-19 and supported the concept of shielding. Shielding allocations and communications were perceived as inconsistently applied and delivered. More than half of those not classified as CEV reported feeling abandoned, at increased risk and with no support. Shielding communications increased feelings of being 'cared about', but also increased fear, and the 'vulnerable' labelling was perceived by some to damage social and self-identity. More than 80% of those classified as CEV stated that the classification and subsequent communications had changed their social-mixing behaviour. Despite many negative impacts of COVID-19 and shielding/lockdown being identified, including isolation, fear and reduced medical care, the quantitative data during the pandemic showed increases in most measures of wellbeing (which was low at both time points) from pre-lockdown, including reductions in the impact of fatigue and pain (

conclusionShielding classifications and communications were, in general, viewed positively, although they were perceived as inconsistently delivered and anxiety-provoking by some participants. More frequent positively framed communication and wellbeing support could benefit all SARD patients. Slower-paced lockdown lifestyles might confer health/wellbeing benefits for some people with chronic diseases.

Indexed as

COVID-19lupusmixed methodspatient behaviourpatient viewsquality of liferheumatologyshieldingsystemic autoimmune rheumatic diseasesystemic lupus erythematosus

Identifiers

PMID33728396
PMCPMC7928599
OpenAlexW3125874260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.